Compare ONC & SLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONC | SLF |
|---|---|---|
| Founded | 2010 | 1871 |
| Country | Switzerland | Canada |
| Employees | 12000 | 68000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4B | 35.4B |
| IPO Year | N/A | N/A |
| Metric | ONC | SLF |
|---|---|---|
| Price | $309.60 | $65.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 1 |
| Target Price | ★ $374.75 | $84.00 |
| AVG Volume (30 Days) | 187.3K | ★ 525.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.94% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $747.23 | N/A |
| Revenue Next Year | $15.78 | $5.30 |
| P/E Ratio | $614.06 | ★ $14.79 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $227.40 | $55.81 |
| 52 Week High | $385.22 | $69.67 |
| Indicator | ONC | SLF |
|---|---|---|
| Relative Strength Index (RSI) | 54.97 | 58.66 |
| Support Level | $307.93 | $61.01 |
| Resistance Level | $320.35 | $66.81 |
| Average True Range (ATR) | 7.68 | 1.18 |
| MACD | 4.77 | 0.42 |
| Stochastic Oscillator | 82.89 | 75.94 |
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Sun Life Financial is one of the Big Three Canadian life insurers. The Canadian business contributed around 35% of its 2025 adjusted earnings. In that segment, the firm provides health, life insurance, and annuity products to individual and group customers. Its US business is mostly group health and contributed about 17% of the firm's adjusted earnings in 2025. Sun Life also offers life insurance and wealth products in several Asian markets with a strong presence in Hong Kong and the Philippines. The Asia segment contributed around 18% of adjusted 2024 earnings. Its asset management business had around CAD 1.2 trillion total assets under management or administration at the end of 2025 and represents around 30% of the firm's earnings.